Use of plasma late on cardiopulmonary bypass in patients undergoing left ventricular assist device implantation

James A. Nelson, Juan C. Diaz Soto, Matthew A. Warner, John M. Stulak, Phillip J. Schulte, Timothy J. Weister, William J. Mauermann, Mark M. Smith

Research output: Contribution to journalArticlepeer-review


Coagulopathy is common during left ventricular assist device (LVAD) implantation, treatment of which can be challenging given the often-limited ability for the right ventricle to accommodate volume transfusion after device initiation with 20% to 40% of patients developing right ventricular failure (RVF). Transfusion of plasma late on cardiopulmonary bypass (CPB) combined with ultrafiltration may replace clotting factors while reducing volume administration. We compared outcomes in patients undergoing LVAD implantation receiving plasma on CPB and ultrafiltration with traditional transfusion practices. Co-primary outcomes needed for blood product transfusion in the first 6 and 24 hours after CPB. Secondary outcomes included metrics of morbidity and mortality. 396 patients were analyzed (59 plasma on CPB). Patients receiving plasma on CPB had a greater volume of blood products transfused (3764 vs. 2741 mL first 6 hours; 6059 vs. 4305 mL first 24 hours) in unadjusted analysis. In adjusted analysis, plasma transfusion on CPB with ultrafiltration had no significant effect on the primary outcomes of blood products given in the first 6 hours (estimated effect size 982 [−428, 2392] mL, P =.17) and 24 hours (estimated effect size 1076 [−904, 3057] mL, P =.29). Patients receiving plasma on CPB were more likely on either vasopressors or inotropes at 24 hours after ICU admission (P =.01), however, indices of coagulopathy and RVF were similar between groups. While prospective studies would be necessary to definitively evaluate the clinical utility of this strategy, no signal for benefit was observed suggesting plasma should not be used for this purpose.

Original languageEnglish (US)
Pages (from-to)491-500
Number of pages10
JournalArtificial Organs
Issue number3
StatePublished - Mar 2022


  • coagulopathy
  • left ventricular assist device implantation
  • plasma on cardiopulmonary bypass
  • right ventricular failure
  • ultrafiltration

ASJC Scopus subject areas

  • Bioengineering
  • Medicine (miscellaneous)
  • Biomaterials
  • Biomedical Engineering


Dive into the research topics of 'Use of plasma late on cardiopulmonary bypass in patients undergoing left ventricular assist device implantation'. Together they form a unique fingerprint.

Cite this